Barbara Melosky

3.4k total citations
116 papers, 2.0k citations indexed

About

Barbara Melosky is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Barbara Melosky has authored 116 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Pulmonary and Respiratory Medicine, 79 papers in Oncology and 18 papers in Cancer Research. Recurrent topics in Barbara Melosky's work include Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Diagnosis and Treatment (33 papers) and Colorectal Cancer Treatments and Studies (30 papers). Barbara Melosky is often cited by papers focused on Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Diagnosis and Treatment (33 papers) and Colorectal Cancer Treatments and Studies (30 papers). Barbara Melosky collaborates with scholars based in Canada, United States and Japan. Barbara Melosky's co-authors include Vera Hirsh, Natasha B. Leighl, Quincy S. Chu, Rosalyn A. Juergens, Cheryl Ho, Parneet Cheema, Esmeralda Celia Marginean, Ronald L. Burkes, Janessa Laskin and Deanna McLeod and has published in prestigious journals such as Journal of Clinical Oncology, The American Journal of Medicine and Annals of Oncology.

In The Last Decade

Barbara Melosky

109 papers receiving 2.0k citations

Peers

Countries citing papers authored by Barbara Melosky

Since Specialization

Citations

This map shows the geographic impact of Barbara Melosky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Melosky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Melosky more than expected).

Fields of papers citing papers by Barbara Melosky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Melosky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Melosky. The network helps show where Barbara Melosky may publish in the future.

Co-authorship network of co-authors of Barbara Melosky

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Melosky. A scholar is included among the top collaborators of Barbara Melosky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Melosky. Barbara Melosky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC 2025 ·Lung Cancer ·Barbara Melosky, Quincy S. Chu, Rosalyn A. Juergens, Stephanie Snow, Normand Blais, Parneet Cheema, Randeep Sangha, Jason Agulnik, (unknown), Ronald L. Burkes, (unknown), Mark Vincent, Geoffrey Liu	0
2	Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer 2024 ·International Journal of Cancer ·Barbara Melosky, Mark Vincent, Anna McGuire, Anthony Brade, Quincy S. Chu, Parneet Cheema, (unknown), Jonathan Spicer, Stephanie Snow, Rosalyn A. Juergens	3
3	Confirmation of Recurrent Lung Cancer Following Resection Using Liquid Biopsy, a Proof-of-Concept Real-World Study 2024 ·Current Oncology ·Julia Naso, Stephen Yip, Curtis Hughesman, Barbara Melosky, (unknown), Melissa K. McConechy, John C. English, Penelope M. A. Brasher, (unknown), Kyle Grant, John Yee, Stephen Lam, Anna McGuire	1
4	Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process 2024 ·Current Oncology ·Anthony Brade, Houda Bahig, Andrea Bezjak, Rosalyn A. Juergens, (unknown), Nicolas Marcoux, Barbara Melosky, Devin Schellenberg, Stephanie Snow	1
5	LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial 2023 ·Annals of Oncology ·Antonio Passaro, Byoung Chul Cho, Yan Wang, Barbara Melosky, Raffaele Califano, SH Lee, Nicolas Girard, Karen L. Reckamp, Toshiaki Takahashi, Enriqueta Felip, Ryan D. Gentzler, Sanjay Popat, William N. William, Tao Sun, Shalin Shah, B. Diorio, Roland E. Knoblauch, Joshua Bauml, M.R. García-Campelo, Jing Wang	8
6	Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience 2023 ·Current Oncology ·(unknown), (unknown), Stephanie Snow, Paul Wheatley‐Price, Barbara Melosky, Rosalyn A. Juergens, Quincy S. Chu, Normand Blais, Shantanu Banerji, Ryan Ng, (unknown), (unknown), (unknown), Geoffrey Liu	4
7	Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer 2023 ·Current Oncology ·Kelly Li, Ian Bosdet, Stephen Yip, Cheryl Ho, Janessa Laskin, Barbara Melosky, (unknown), Sophie Sun	1
8	Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC 2023 ·Current Oncology ·Parneet Cheema, Shantanu Banerji, Normand Blais, Quincy S. Chu, Rosalyn A. Juergens, Natasha B. Leighl, Adrian G. Sacher, Brandon S. Sheffield, Stephanie Snow, Mark Vincent, (unknown), Stephen Yip, Barbara Melosky	1
9	Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years 2023 ·Current Oncology ·(unknown), Cheryl Ho, (unknown), Jianjun Zhang, (unknown), Jessica Li, Montgomery Martin, Lang Wu, Ying Wang, Stephen Lam, Calum MacAulay, Barbara Melosky, Ren Yuan	2
10	Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process 2023 ·Current Oncology ·James Tankel, Jonathan Spicer, Quincy S. Chu, Pierre Fiset, Biniam Kidane, Natasha B. Leighl, Philippe Joubert, Donna E. Maziak, David A. Palma, Anna McGuire, Barbara Melosky, Stephanie Snow, Houda Bahig, Normand Blais	4
11	Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression 2023 ·Current Oncology ·(unknown), (unknown), (unknown), (unknown), Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, (unknown), Cheryl Ho, Barbara Melosky	7
12	Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations 2023 ·Lung Cancer ·A. Sun, Bassam Abdulkarim, Normand Blais, Jonathan Greenland, Alexander V. Louie, Barbara Melosky, Devin Schellenberg, Stephanie Snow, Geoffrey Liu	13
13	The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis 2022 ·Current Oncology ·Anna McGuire, Melissa K. McConechy, Barbara Melosky, John C. English, (unknown), (unknown), John Yee, Benjamin L. S. Furman, (unknown), Pedro Feijão, David T. Mulder, Curtis Hughesman, Stephen Yip	7
14	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer 2022 ·Current Oncology ·Diana N. Ionescu, Tracy Stockley, Shantanu Banerji, Christian Couture, (unknown), Zhaolin Xu, Normand Blais, Parneet Cheema, Quincy S. Chu, Barbara Melosky, Natasha B. Leighl	20
15	A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib 2022 ·Current Oncology ·(unknown), (unknown), Tracy Tucker, Diana N. Ionescu, Barbara Melosky	11
16	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients 2021 ·Current Oncology ·(unknown), Don Husereau, Natasha B. Leighl, Barbara Melosky, Julian Nam	13
17	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer 2021 ·Therapeutic Advances in Medical Oncology ·Barbara Melosky, Parneet Cheema, Rosalyn A. Juergens, Natasha B. Leighl, Geoffrey Liu, Paul Wheatley‐Price, Adrian G. Sacher, Stephanie Snow, Ming‐Sound Tsao, Deanna McLeod, Quincy S. Chu	4
18	Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations 2021 ·Future Oncology ·Edward S. Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James Chih‐Hsin Yang	18
19	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer 2021 ·Lung Cancer ·Barbara Melosky, Paul Wheatley‐Price, Rosalyn A. Juergens, Adrian G. Sacher, Natasha B. Leighl, Ming‐Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, (unknown), Quincy S. Chu	51
20	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer 2019 ·Lung Cancer ·Barbara Melosky, Rosalyn A. Juergens, Deanna McLeod, Natasha B. Leighl, Anthony Brade, (unknown), Quincy S. Chu	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact